Communication is Key When Transitioning Multiple Myeloma Care
A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient Multiple Myeloma Summit.
Read More
Top 3 Takeaways From ASCO GU 2025
Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.
Watch
Emphasizing the Importance of Breast Cancer Education and Screenings
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Evolving Treatments and Advances in HER2-Positive Breast Cancer
Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.
The Power of Knowledge and Staying Informed in Breast Cancer Care
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
What Patients With Breast Cancer Need to Know About Itovebi
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.
Gene Expression Testing and Targeted Therapies in Breast Cancer Care
Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.
Understanding Genetic and Genomic Testing in Breast Cancer
Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.
Why It’s Important to Have Hard Conversations in Breast Cancer Care
CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.
Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.
Targeted Axillary Dissection Offers a Precise Option in Breast Cancer
Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.
Guiding Patients Through Shared Decision-Making in Breast Cancer Care
Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.
Understanding the Best Practices Associated With CDK4/6 Therapy in Breast Cancer
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
COSMIC-313 Trial Lead Breaks Down Treatment Intensification in RCC
Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.
Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC
In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.
Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer
Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.
Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC
Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.
UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.
Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.
An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.
Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma
Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.
Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC
Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.
Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
